Cargando…

Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice

BACKGROUND: Osteoporosis is a silent disease caused by low bone mineral density that results in bone fractures in 1 out of 2 women and 1 in 4 men over the age of 50. Although several treatments for osteopenia and osteoporosis are available, they have severe side effects and new treatments are desper...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, John, Weidner, Hilary, Schell, Lora M., Sequeira, Linda, Kabrick, Ryan, Dharmadhikari, Saurabh, Coombs, Harold, Duncan, Randall L., Wang, Liyun, Nohe, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173331/
https://www.ncbi.nlm.nih.gov/pubmed/30294717
http://dx.doi.org/10.4172/2572-4916.1000190
_version_ 1783361104881123328
author Nguyen, John
Weidner, Hilary
Schell, Lora M.
Sequeira, Linda
Kabrick, Ryan
Dharmadhikari, Saurabh
Coombs, Harold
Duncan, Randall L.
Wang, Liyun
Nohe, Anja
author_facet Nguyen, John
Weidner, Hilary
Schell, Lora M.
Sequeira, Linda
Kabrick, Ryan
Dharmadhikari, Saurabh
Coombs, Harold
Duncan, Randall L.
Wang, Liyun
Nohe, Anja
author_sort Nguyen, John
collection PubMed
description BACKGROUND: Osteoporosis is a silent disease caused by low bone mineral density that results in bone fractures in 1 out of 2 women and 1 in 4 men over the age of 50. Although several treatments for osteopenia and osteoporosis are available, they have severe side effects and new treatments are desperately needed. Current treatments usually target osteoclasts and inhibit their activity or differentiation. Treatments that decrease osteoclast differentiation and activity but enhance osteogenesis and osteoblast activity are not available. We recently developed a peptide, CK2.3, that induces bone formation and increases bone mineral density as demonstrated by injection over the calvaria of 6 to 9-day-old mice and tail vein injection of 8-week-old mice. CK2.3 also decreased osteoclast formation and activity. However, these studies raise questions: does CK2.3 induce similar results in old mice and if so, what is the effective CK2.3 concentration and, is the bone mineral density of vertebrae of the spinal column increased as well? METHODS: CK2.3 was systematically injected into the tail vein of female 6-month old mice with various concentrations of CK2.3: 0.76 μg/kg, 2.3 μg/kg, or 6.9 μg/kg per mice. Mice were sacrificed one week, two weeks, and four weeks after the first injection. Their spines and femurs were collected and analyzed for bone formation. RESULTS: Femur and lumbar spine analyses found increased bone mineral density (BMD) and mineral apposition rate, with greater stiffness observed in femoral samples four weeks after the first injection. Histochemistry showed that osteoclastogenesis was suppressed in CK2.3 treated senile mice. CONCLUSIONS: For the first time, this study showed the increase of lumbar spine BMD by CK2.3. Moreover, it showed that enhancement of femur BMD was accompanied by increased femur stiffness only at medium concentration of CK2.3 four weeks after the first injection indicating the maintenance of bone’s structural integrity by CK2.3.
format Online
Article
Text
id pubmed-6173331
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-61733312018-10-05 Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice Nguyen, John Weidner, Hilary Schell, Lora M. Sequeira, Linda Kabrick, Ryan Dharmadhikari, Saurabh Coombs, Harold Duncan, Randall L. Wang, Liyun Nohe, Anja J Bone Res Article BACKGROUND: Osteoporosis is a silent disease caused by low bone mineral density that results in bone fractures in 1 out of 2 women and 1 in 4 men over the age of 50. Although several treatments for osteopenia and osteoporosis are available, they have severe side effects and new treatments are desperately needed. Current treatments usually target osteoclasts and inhibit their activity or differentiation. Treatments that decrease osteoclast differentiation and activity but enhance osteogenesis and osteoblast activity are not available. We recently developed a peptide, CK2.3, that induces bone formation and increases bone mineral density as demonstrated by injection over the calvaria of 6 to 9-day-old mice and tail vein injection of 8-week-old mice. CK2.3 also decreased osteoclast formation and activity. However, these studies raise questions: does CK2.3 induce similar results in old mice and if so, what is the effective CK2.3 concentration and, is the bone mineral density of vertebrae of the spinal column increased as well? METHODS: CK2.3 was systematically injected into the tail vein of female 6-month old mice with various concentrations of CK2.3: 0.76 μg/kg, 2.3 μg/kg, or 6.9 μg/kg per mice. Mice were sacrificed one week, two weeks, and four weeks after the first injection. Their spines and femurs were collected and analyzed for bone formation. RESULTS: Femur and lumbar spine analyses found increased bone mineral density (BMD) and mineral apposition rate, with greater stiffness observed in femoral samples four weeks after the first injection. Histochemistry showed that osteoclastogenesis was suppressed in CK2.3 treated senile mice. CONCLUSIONS: For the first time, this study showed the increase of lumbar spine BMD by CK2.3. Moreover, it showed that enhancement of femur BMD was accompanied by increased femur stiffness only at medium concentration of CK2.3 four weeks after the first injection indicating the maintenance of bone’s structural integrity by CK2.3. 2018-06-30 2018 /pmc/articles/PMC6173331/ /pubmed/30294717 http://dx.doi.org/10.4172/2572-4916.1000190 Text en Open Access This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited http//creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Nguyen, John
Weidner, Hilary
Schell, Lora M.
Sequeira, Linda
Kabrick, Ryan
Dharmadhikari, Saurabh
Coombs, Harold
Duncan, Randall L.
Wang, Liyun
Nohe, Anja
Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice
title Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice
title_full Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice
title_fullStr Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice
title_full_unstemmed Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice
title_short Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice
title_sort synthetic peptide ck2.3 enhances bone mineral density in senile mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173331/
https://www.ncbi.nlm.nih.gov/pubmed/30294717
http://dx.doi.org/10.4172/2572-4916.1000190
work_keys_str_mv AT nguyenjohn syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT weidnerhilary syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT schellloram syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT sequeiralinda syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT kabrickryan syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT dharmadhikarisaurabh syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT coombsharold syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT duncanrandalll syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT wangliyun syntheticpeptideck23enhancesbonemineraldensityinsenilemice
AT noheanja syntheticpeptideck23enhancesbonemineraldensityinsenilemice